PDCD1LG2 and esophageal cancer: Studies have found that strong PD-L2 expression in a variety of tumor tissues can play a negative role in tumor immune escape and predict poor overall survival, such as in liver cancer 22, esophageal cancer 23, prostate cancer 24, bladder cancer 25 and lung adenocarcinoma 26.